Philip Crispin

Dr. Philip Crispin


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2023 in Critical Care
Verified
Journal Article
Open access
PDF file
LCLucy A. Coupland
Lucy A. Coupland
DRDavid John Rabbolini
David John Rabbolini
JSJonathan G. Schoenecker
Jonathan G. Schoenecker
PCPhilip Crispin
Philip Crispin
JMJennene J. Miller
Jennene J. Miller
AAAnders Aneman
Anders Aneman
Background: Fibrinolysisis is essential for vascular blood flow maintenance and is triggered by endothelial and platelet release of tissue plasminogen activator (t-PA). In certain critical conditions, e.g. sepsis, acute respiratory failure (ARF) and trauma, the fibrinolytic response is reduced and may lead to widespread thrombosis and multi-organ failure. The mechanisms underpinning fibrinolysis resistance include reduced t-PA expression and/or release, reduced t-PA and/or plasmin effect due to elevated inhibitor levels, increased consumption and/or clearance. This study in critically ill patients with fibrinolysis resistance aimed to evaluate the ability of t-PA and plasminogen supplementation to restore fibrinolysis with assessment using point-of-care ClotPro viscoelastic testing (VET). Methods: In prospective, observational studies, whole-blood ClotPro VET evaluation was carried out in 105 critically ill patients. In 32 of 58 patients identified as fibrinolysis-resistant (clot lysis time > 300 s on the TPA-test: tissue factor activated coagulation with t-PA accelerated fibrinolysis), consecutive experimental whole-blood VET was carried out with repeat TPA-tests spiked with additional t-PA and/or plasminogen and the effect on lysis time determined. In an interventional study in a patient with ARF and fibrinolysis resistance, the impact of a 24 h intravenous low-dose alteplase infusion on coagulation and fibrinolysis was prospectively monitored using standard ClotPro VET. Results: Distinct response groups emerged in the ex vivo experimental VET, with increased fibrinolysis observed following supplementation with (i) t-PA only or (ii) plasminogen and t-PA. A baseline TPA-test lysis time of > 1000 s was associated with the latter group. In the interventional study, a gradual reduction (25%) in serial TPA-test lysis times was observed during the 24 h low-dose alteplase infusion. Conclusions: ClotPro viscoelastic testing, the associated TPA-test and the novel experimental assays may be utilised to (i) investigate the potential mechanisms of fibrinolysis resistance, (ii) guide corrective treatment and (iii) monitor in real-time the treatment effect. Such a precision medicine and personalised treatment approach to the management of fibrinolysis resistance has the potential to increase treatment benefit, while minimising adverse events in critically ill patients. Trial registration: VETtiPAT-ARF, a clinical trial evaluating ClotPro-guided t-PA (alteplase) administration in fibrinolysis-resistant patients with ARF, is ongoing (ClinicalTrials.gov NCT05540834; retrospectively registered September 15th 2022).

8 October 2019 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
DTDan Dan Tian
Dan Dan Tian
SBSamuel K. Bennett
Samuel K. Bennett
LCLucy A. Coupland
Lucy A. Coupland
KFKathryn Forwood
Kathryn Forwood
YLYadanar Lwin
Yadanar Lwin
ABAnneke Blackburn
Anneke Blackburn
Dichloroacetate (DCA) is an investigational drug targeting the glycolytic hallmark of cancer by inhibiting pyruvate dehydrogenase kinases (PDK). It is metabolized by GSTZ1, which has common polymorphisms altering enzyme or promoter activity. GSTZ1 is also irreversibly inactivated by DCA. In the first clinical trial of DCA in a hematological malignancy, DiCAM (DiChloroAcetate in Myeloma), we have examined the relationship between DCA concentrations, GSTZ1 genotype, side effects, and patient response. DiCAM recruited seven myeloma patients in partial remission. DCA was administered orally for 3 months with a loading dose. Pharmacokinetics were performed on day 1 and 8. Trough and peak concentrations of DCA were measured monthly. GSTZ1 genotypes were correlated with drug concentrations, tolerability, and disease outcomes. One patient responded and two patients showed a partial response after one month of DCA treatment, which included the loading dose. The initial half‐life of DCA was shorter in two patients, correlating with heterozygosity for GSTZ1*A genotype, a high enzyme activity variant. Over 3 months, one patient maintained DCA trough concentrations approximately threefold higher than other patients, which correlated with a low activity promoter genotype (−1002A, rs7160195) for GSTZ1. This patient displayed the strongest response, but also the strongest neuropathy. Overall, serum concentrations of DCA were sufficient to inhibit the constitutive target PDK2, but unlikely to inhibit targets induced in cancer. Promoter GSTZ1 polymorphisms may be important determinants of DCA concentrations and neuropathy during chronic treatment. Novel dosing regimens may be necessary to achieve effective DCA concentrations in most cancer patients while avoiding neuropathy.

4 November 2014 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
SPSagun Parakh
Sagun Parakh
APA. Piggin
A. Piggin
TNT. Neeman
T. Neeman
IMI. Mitchell
I. Mitchell
PCPhilip Crispin
Philip Crispin
ADA. Davis
A. Davis

26 October 2010 in Journal of Paediatrics and Child Health
Verified
Journal Article
Closed access
PDF file
ADAlexander Dillon
Alexander Dillon
TCTejasvi Chaudhari
Tejasvi Chaudhari
PCPhilip Crispin
Philip Crispin
BSBruce Shadbolt
Bruce Shadbolt
AKAlison Kent
Alison Kent

1 August 2021 in Carbohydrate Polymers
Verified
Journal Article
Closed access
EMElmira Mohamed
Elmira Mohamed
LCLucy A. Coupland
Lucy A. Coupland
PCPhilip Crispin
Philip Crispin
AFAilene Fitzgerald
Ailene Fitzgerald
David NisbetDavid Nisbet
David Nisbet
TTTakuya Tsuzuki
Takuya Tsuzuki

1 January 2021 in Transfusion Medicine Reviews
Verified
Journal Article
Closed access
PCPhilip Crispin
Philip Crispin
KFKathryn Forwood
Kathryn Forwood